Intl. Congress form | International Congress Report | International Congress Report For Faculty | Global Spine Congress 2017 by Dr. Vafa Rahimi-Movaghar

Home

Code : 9345-353259 Created Date : Monday, August 7, 2017 Visit : 1657

Global Spine Congress 2017 by Dr. Vafa Rahimi-Movaghar

Application Code :

762-0117-0019

Created Date : Friday, April 28, 2017-19:16 19:16:07Update Date : Wednesday, July 5, 2017-10:12 10:12:09
IP Address : 194.225.54.146Submit Date : Wednesday, July 5, 2017-10:13 10:13:03Email : v_rahimi@sina.tums.ac.ir

Personal Information

Name :	Vafa
Surname :	Rahimi-Movaghar
School/Research center :	Sina Trauma and Surgery Research Center (STSRC)
If you choose other, please name your Research center :
Position :	Professor
Tel :	+216-675-7010

Information of Congress

Title of the Congress :	Global Spine Congress 2017
Title of your Abstract :	Evidence-based prevention and treatment of osteoporosis after spinal cord injury: A Systematic Review
Destination Country :	Italy
From :	Wednesday, May 3, 2017
To :	Saturday, May 6, 2017
Abstract(Please copy/paste the abstract send to the congress) :	Evidence-based prevention and treatment of osteoporosis after spinal cord injury: A Systematic Review Authors: Ali Yousefian1 Radin Maheronnaghsh1 Saeed Soleyman-Jahi2 Farhad Shokraneh3 Akbar Soltani4 Seyed Mostafa Hosseini5 Alexander R Vaccaro6 Vafa Rahimi-Movaghar1,7 1Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran 2Medical School, Tehran University of Medical Sciences, Tehran, Iran 3Cochrane Schizophrenia Group, the Institute of Mental Health, a partnership between the University of Nottingham and Nottinghamshire Healthcare NHS Trust, Nottingham, United Kingdom 4Endocrinology & Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran 5Department of Epidemiology and Biostatistics, School of Public Health and Institute of Public Health Research, Tehran University of Medical Sciences , Tehran, Iran 6Department of Orthopedics and Neurosurgery, Thomas Jefferson University and the Rothman Institute, Philadelphia, PA, USA 7Research Centre for Neural Repair, University of Tehran, Tehran, Iran Corresponding author: Vafa Rahimi-Movaghar, MD, Professor of Neurosurgery 1- Sina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran 2- Research Centre for Neural Repair, University of Tehran, Tehran, Iran Address: Sina Trauma and Surgery Research Center, Sina Hospital, Hassan-Abad Square, Imam Khomeini Ave, Tehran University of Medical Sciences, Tehran, 11365-3876, Iran Phone: (+98) 915 342 2682, (+98) 216 675 7001 Fax: (+98) 216 675 7009 Email: v_rahimi@sina.tums.ac.ir Email: v_rahimi@yahoo.com Funding: The study was supported by AOSME (AOSpine of Middle East) and Sina Trauma and Research Center of Tehran University of Medical Sciences. Competing interest: None. Contributors: All authors contributed in data gathering and writing and editing the draft of the manuscript. All authors read and approved the final version of manuscript. Short running title: Osteoporosis after spinal cord injury Key points 1. Many studies were small and of poor quality, and none included fracture outcomes. Therefore, available data is insufficient to endorse the routine use of any of the proposed interventions for fracture prevention in patients with SCI. 2. There was low to moderate quality evidence that use of Bisphosphonates is effective in the prevention or treatment of bone loss in the first year after injury. The evidence for Clodronate is moderate-quality and for Etidronate, Alendronate, Zoledronic acid is low-quality. 3. There was low-quality evidence that use of Vitamin-D analogous and Alendronate plus calcium is effective in the prevention or treatment of bone loss for one year and beyond. 4. There was low-quality evidence that electrical stimulation is useful in preventing bone loss after acute SCI. 5. For other rehabilitation modalities after SCI evidence is lacking to draw any conclusions in preventing bone loss. Mini-abstract Our systematic review showed that there was low to moderate quality evidence for Bisphosphonates efficacy in the prevention/treatment of bone loss in the first year after spinal cord injury (SCI) and low-quality evidence for Vitamin-D analogous and Alendronate plus calcium for ≥one year and for electrical stimulation in acute SCI. Abstract Study Design: Systematic review Summary of Background Data: Spinal cord injury (SCI) leads to a profound reduction in bone mineral density (BMD) and disturbances of the skeletal trabecular microarchitecture. The pathogenesis of osteoporosis after SCI is complex and differs from other forms of this problem. Objective: The aim of this study is to review the most recent literature on evidence-based prevention and treatments of osteoporosis in SCI patients. Methods: The Cochrane Library, EMBASE (excluding MEDLINE) (1974 – 2015 Week 24), MEDLINE (1946 – June 17, 2015), and PubMed (excluding MEDLINE) (1946 – June 17, 2015) were comprehensively searched. The search strategy involved the following keywords: spinal cord injury, osteoporosis, bone loss, evidence, screening, and treatment. Results: A total of 51 studies met inclusion criteria. Fifteen out of 51 were randomized controlled trials involving 356 patients. Many studies were small and of poor quality, and none included fracture outcomes. There was low to moderate quality evidence that use of Bisphosphonates is effective in the prevention or treatment of bone loss in the first year after injury. The evidence for Clodronate is moderate-quality and for Etidronate, Alendronate, Zoledronic acid is low-quality. There was low-quality evidence that use of Vitamin-D analogous and Alendronate plus calcium is effective in the prevention or treatment of bone loss for one year and beyond. There was low-quality evidence that electrical stimulation is useful in preventing bone loss after acute SCI. For other rehabilitation modalities after SCI evidence is lacking to draw any conclusions in preventing bone loss. Conclusions: Available data is insufficient to endorse the routine use of any of the proposed interventions for fracture prevention in patients with SCI.
Keywords of your Abstract :	spinal cord injury, osteoporosis, bone loss, evidence, rehabilitation, prevention, screening, treatment
Acceptance Letter :	http://gsia.tums.ac.ir/images/UserFiles/23848/Forms/762/Osteoporosis_VRM_Poster_Milan_2.pdf
The presentation :	Poster
The Cover of Abstract book :	http://gsia.tums.ac.ir/images/UserFiles/23848/Forms/762/Abstract book cover_1.pdf
Published abstract in the abstract book with the related code :	http://gsia.tums.ac.ir/images/UserFiles/23848/Forms/762/Abstract_PDF.pdf
Where has your abstract been indexed? :	none
If you choose other, please name :

The Congress Reporting Form

How many volunteers were present at the Congress? :	1400
Delegates from which countries presented in the congress? :	All over the world - USA, Italy, China, Japan, Germany, Iran, Egypt, Turkey, USSR, Brazil, Mexico
Were the delegates of any other organizations present in the congress? :	Yes
If yes, please write the names of the organizations in the box :	American Spine Society, NAAS
What were the responses to your talking points? Were specific questions or concerns raised? :	My presentation was e-poster. No specific question was performed. However, the study was a systematic review about Evidence-based prevention and treatment of osteoporosis after spinal cord injury with the level of evidence of 1A. Based on the extensive literature search, we found the following points: 1. Many studies were small and of poor quality, and none included fracture outcomes. Therefore, available data is insufficient to endorse the routine use of any of the proposed interventions for fracture prevention in patients with SCI. 2. There was low to moderate quality evidence that use of Bisphosphonates is effective in the prevention or treatment of bone loss in the first year after injury. The evidence for Clodronate is moderate-quality and for Etidronate, Alendronate, Zoledronic acid is low-quality. 3. There was low-quality evidence that use of Vitamin-D analogous and Alendronate plus calcium is effective in the prevention or treatment of bone loss for one year and beyond. 4. There was low-quality evidence that electrical stimulation is useful in preventing bone loss after acute SCI. 5. For other rehabilitation modalities after SCI evidence is lacking to draw any conclusions in preventing bone loss.
If you met staff members, please list their full names & positions. :	Jeffrey Wang: Congress Chairperson; Daniel K. Riew: Congress co-chairperson; Michael Grevitt: Congress Co-Chairperson; Michael Fehlings: Knowledge Forum of SCI; Bizhan Aarabi: American Spine Surgeon; I met most giants of the spine in the world.
Please inform us if there are any follow up actions we need to talk with the members of the congress :	There is no follow up actions you need to talk with the members of the congress. However, our study was about an interesting title. You would give our study to the professors and residents of neurosurgery and spine surgery: Study Design: Systematic review Summary of Background Data: Spinal cord injury (SCI) leads to a profound reduction in bone mineral density (BMD) and disturbances of the skeletal trabecular microarchitecture. The pathogenesis of osteoporosis after SCI is complex and differs from other forms of this problem. Objective: The aim of this study is to review the most recent literature on evidence-based prevention and treatments of osteoporosis in SCI patients. Methods: The Cochrane Library, EMBASE (excluding MEDLINE) (1974 – 2015 Week 24), MEDLINE (1946 – June 17, 2015), and PubMed (excluding MEDLINE) (1946 – June 17, 2015) were comprehensively searched. The search strategy involved the following keywords: spinal cord injury, osteoporosis, bone loss, evidence, screening, and treatment. Results: A total of 51 studies met inclusion criteria. Fifteen out of 51 were randomized controlled trials involving 356 patients. Many studies were small and of poor quality, and none included fracture outcomes. There was low to moderate quality evidence that use of Bisphosphonates is effective in the prevention or treatment of bone loss in the first year after injury. The evidence for Clodronate is moderate-quality and for Etidronate, Alendronate, Zoledronic acid is low-quality. There was low-quality evidence that use of Vitamin-D analogous and Alendronate plus calcium is effective in the prevention or treatment of bone loss for one year and beyond. There was low-quality evidence that electrical stimulation is useful in preventing bone loss after acute SCI. For other rehabilitation modalities after SCI evidence is lacking to draw any conclusions in preventing bone loss. Conclusions: Available data is insufficient to endorse the routine use of any of the proposed interventions for fracture prevention in patients with SCI.
Your experiences about the travel processes(Providing ticket, accommodation,...) :	Extremely expensive and difficult. The visa issue was frustrating and I paid 11 million tuman extra money for visa appointment. Because there was a great problem for online visa appointment.
Please give a briefing of your own observations and outcomes of the congress: :	Congress was in the highest level and fantastic. Presentation of lecture by cartoon and video by MG Fehlings was the highlight of the congress. My study was an interesting subject and it was in the continuation of my previous systematic review published in Cochrane. Our systematic review showed that there was low to moderate quality evidence for Bisphosphonates efficacy in the prevention/treatment of bone loss in the first year after spinal cord injury (SCI) and low-quality evidence for Vitamin-D analogous and Alendronate plus calcium for ≥one year and for electrical stimulation in acute SCI. 1. Many studies were small and of poor quality, and none included fracture outcomes. Therefore, available data is insufficient to endorse the routine use of any of the proposed interventions for fracture prevention in patients with SCI. There was low to moderate quality evidence that use of Bisphosphonates is effective in the prevention or treatment of bone loss in the first year after injury. The evidence for Clodronate is moderate-quality and for Etidronate, Alendronate, Zoledronic acid is low-quality. There was low-quality evidence that use of Vitamin-D analogous and Alendronate plus calcium is effective in the prevention or treatment of bone loss for one year and beyond. There was low-quality evidence that electrical stimulation is useful in preventing bone loss after acute SCI. For other rehabilitation modalities after SCI evidence is lacking to draw any conclusions in preventing bone loss.

Home Printer Friendly Tell a Friend Comment

Your Comments :